Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study

Psoriasis

Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate to Severe Psoriasis up to 3 Years of Treatment: Results from A Double-Blind Extension Study

Br J Dermatol.

Bissonnette R, Luger T, Thaçi D, Toth D, Messina I, You R, Guana A, Fox T, Papavassilis C, Gilloteau I, Mrowietz U

doi: 10.1111/bjd.15706.

Psoriasis

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study

J Am Acad Dermatol.

Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, Kianifard F, Nyirady J, Lebwohl M

doi: 10.1016/j.jaad.2017.05.033.

AcnePsoriasis

Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis: Results from the EXCEED, a randomised, double-blind head-to-head monotherapy study

Br J Dermatol

Gottlieb AB, Merola JF, Reich K, Behrens F, Nash P, Griffiths CEM, Bao W, Pellet P, Pricop L, McInnes IB

doi: 10.1111/bjd.20413

PsoriasisPsoriatic Arthritis

Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study)

J Eur Acad Dermatol Venereol.

Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R, Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U

doi: 10.1111/jdv.14878.

Psoriasis

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial

Br J Dermatol.

Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, Geng Z, Paul C

doi: 10.1111/bjd.19341.

COMMENTED

Psoriasis

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study

Br J Dermatol.

Papini M, Cusano F, Romanelli M, Burlando M, Stinco G, Girolomoni G, Peris K, Potenza C, Offidani A, Bartezaghi M, Aloisi E, Costanzo A, SUPREME study group

doi: 10.1111/bjd.18013.

Psoriasis

Sustained Efficacy of Secukinumab in Subjects with Moderate-to-Severe Palmoplantar Psoriasis: 2·5-Year Results from GESTURE, a Randomized, Double-blind, Placebo-controlled Trial

Br J Dermatol.

Gottlieb AB, Kubanov A, van Doorn M, Sullivan J, Papp KA, You R, Regnault P, Frueh JA

doi: 10.1111/bjd.18331.

Psoriasis

Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response

J Eur Acad Dermatol Venereol.

Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB

doi: 10.1111/jdv.15277.

Psoriasis

First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis

J Eur Acad Dermatol Venereol

Kaul M, Jarvis P, Rozenberg I, Kolbinger F, Di Padova F, Calonder C, Espie P, Rondeau JM, Cebe R, Huber T, Mussmann R, Aassi M, Sligh TS

doi: 10.1111/jdv.17071

Related content

Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate to Severe Psoriasis up to 3 Years of Treatment: Results from A Double-Blind Extension Study

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study

Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis: Results from the EXCEED, a randomised, double-blind head-to-head monotherapy study

Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study)

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study

Sustained Efficacy of Secukinumab in Subjects with Moderate-to-Severe Palmoplantar Psoriasis: 2·5-Year Results from GESTURE, a Randomized, Double-blind, Placebo-controlled Trial

Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response

First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis